Anti-metabolites
Reduced-Intensity Stem Cell Transplant for Non-Malignant Disorders
Recruiting1 awardPhase 2
Pittsburgh, Pennsylvania
This trial is testing whether a reduced-intensity conditioning regimen followed by umbilical cord blood transplant, double cord blood transplant, matched unrelated donor bone marrow transplant, or peripheral blood stem cell transplant is effective in treating patients with non-malignant disorders.
CAR T-cell Therapy
NST Therapy for Chronic Norovirus in Immunocompromised Patients
Recruiting1 awardPhase 1
Washington, District of Columbia
This trial will test a new therapy for people with a chronic norovirus infection who have either had a stem cell transplant or who have a primary immunodeficiency disorder.
Virus Therapy
Tabelecleucel for EBV Associated Diseases
Recruiting1 awardPhase 2
Orange, California
This trial tests tabelecleucel, a treatment using special immune cells, in patients with certain diseases related to the Epstein-Barr virus (EBV) who can't use or don't respond to standard treatments. It works by enhancing the immune system's ability to attack virus-infected cells. Tabelecleucel is being tested for recurring or hard-to-treat EBV-related diseases.
Popular Filters
Trials for PID Patients
Immunoglobulin Replacement Therapy
TAK-881 for Primary Immunodeficiency
Recruiting2 awardsPhase 3
Macon, Georgia
"This trial aims to determine if TAK-881 is safe for long-term use in adults and children with Primary Immunodeficiency Disorder who completed a previous study. Participants will receive TAK-881 inf
Immunoglobulin
Newnorm for Primary Immunodeficiency
Recruiting2 awardsPhase 3
Overland Park, Kansas
This trial is testing a new antibody treatment called Newnorm, which is given through an injection under the skin. It aims to help people with primary immunodeficiency diseases, whose immune systems are weak. The treatment provides extra antibodies to help their bodies fight infections.
Hematopoietic Stem Cell Transplantation
Haploidentical HCT for Primary Immunodeficiency
Recruiting2 awardsPhase 2
Saint Petersburg, Florida
This trial is testing a new way to do a haploidentical transplant, using TCR alpha beta and CD19 depleted stem cells from a donor. The hope is that this will be a safe and effective way to treat the patient's underlying condition.
Antimetabolites
Reduced Intensity BMT + Cyclophosphamide for Primary Immunodeficiency & Bone Marrow Failure
Recruiting3 awardsPhase 2
Baltimore, Maryland
This trial will study how well a reduced intensity conditioning hematopoietic stem cell transplant (HSCT) and post-transplant cyclophosphamide (PTCy) work in patients with primary immune deficiencies (PID), immune dysregulatory syndromes (IDS), and inherited bone marrow failure syndromes (IBMFS).
Stem Cell Therapy
CD34+ Stem Cell Selection for Bone Marrow Failure Syndromes
Recruiting1 awardPhase 1 & 2
New York, New York
This trial uses a special machine to filter out harmful cells from donor blood to make stem cell transplants safer for young patients with non-cancerous diseases. By removing specific cells, it aims to prevent a serious immune reaction.
Trials With No Placebo
Behavioural Intervention
Markers for Primary Immunodeficiency
Recruiting1 award
Tampa, Florida
This trial aims to better understand and find effective treatments for autoimmune cytopenias, which are common in patients with immune system disorders. Current treatments often fail, leading to high costs and health risks. The
Immunoglobulin Replacement Therapy
TAK-881 for Primary Immunodeficiency
Recruiting2 awardsPhase 3
Macon, Georgia
"This trial aims to determine if TAK-881 is safe for long-term use in adults and children with Primary Immunodeficiency Disorder who completed a previous study. Participants will receive TAK-881 inf
Immunoglobulin
Newnorm for Primary Immunodeficiency
Recruiting2 awardsPhase 3
Overland Park, Kansas
This trial is testing a new antibody treatment called Newnorm, which is given through an injection under the skin. It aims to help people with primary immunodeficiency diseases, whose immune systems are weak. The treatment provides extra antibodies to help their bodies fight infections.
Hematopoietic Stem Cell Transplantation
Haploidentical HCT for Primary Immunodeficiency
Recruiting2 awardsPhase 2
Saint Petersburg, Florida
This trial is testing a new way to do a haploidentical transplant, using TCR alpha beta and CD19 depleted stem cells from a donor. The hope is that this will be a safe and effective way to treat the patient's underlying condition.
Antimetabolites
Reduced Intensity BMT + Cyclophosphamide for Primary Immunodeficiency & Bone Marrow Failure
Recruiting3 awardsPhase 2
Baltimore, Maryland
This trial will study how well a reduced intensity conditioning hematopoietic stem cell transplant (HSCT) and post-transplant cyclophosphamide (PTCy) work in patients with primary immune deficiencies (PID), immune dysregulatory syndromes (IDS), and inherited bone marrow failure syndromes (IBMFS).
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.